News & Updates
Filter by Specialty:
KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).
KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
09 Oct 2024
In utero exposure to flu spells increased risk of childhood seizures
Infants born to mothers who contracted influenza infection during pregnancy are at heightened risk of seizures, particularly febrile seizures, during childhood, according to a large study.
In utero exposure to flu spells increased risk of childhood seizures
03 Oct 2024
Epilepsy and ASM use in pregnancy increase morbidity and mortality risks in women and their offspring
Women with epilepsy are at considerably higher risk of severe maternal and perinatal outcomes and increased risk of death during pregnancy and postpartum, and the use of antiseizure medications (ASM) further increases these risks, the largest study to date has found.
Epilepsy and ASM use in pregnancy increase morbidity and mortality risks in women and their offspring
03 Oct 2024
Maternal food insecurity tied to adverse pregnancy outcomes
Pregnant women with food insecurity are at greater risk of developing some adverse pregnancy outcomes, such as mental health problems and gestational diabetes mellitus (GDM), suggests a study.